NZ751915B2 - Non-irritating ophthalmic povidone-iodine compositions - Google Patents
Non-irritating ophthalmic povidone-iodine compositions Download PDFInfo
- Publication number
- NZ751915B2 NZ751915B2 NZ751915A NZ75191510A NZ751915B2 NZ 751915 B2 NZ751915 B2 NZ 751915B2 NZ 751915 A NZ751915 A NZ 751915A NZ 75191510 A NZ75191510 A NZ 75191510A NZ 751915 B2 NZ751915 B2 NZ 751915B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- ophthalmic preparation
- steroidal anti
- preparation
- ophthalmic
- eye
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229920000153 Povidone-iodine Polymers 0.000 title claims abstract description 26
- 229960001621 povidone-iodine Drugs 0.000 title claims abstract description 26
- 231100000344 non-irritating Toxicity 0.000 title description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 59
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 230000003637 steroidlike Effects 0.000 claims abstract description 34
- 230000003110 anti-inflammatory Effects 0.000 claims abstract description 33
- 239000002826 coolant Substances 0.000 claims abstract description 27
- 239000000314 lubricant Substances 0.000 claims abstract description 19
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 206010023332 Keratitis Diseases 0.000 claims description 24
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 230000000069 prophylaxis Effects 0.000 claims description 23
- 210000001519 tissues Anatomy 0.000 claims description 21
- 244000005700 microbiome Species 0.000 claims description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 15
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 208000009745 Eye Disease Diseases 0.000 claims description 11
- 229940068984 Polyvinyl Alcohol Drugs 0.000 claims description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 11
- -1 light mineral oil Polymers 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims description 9
- 206010010984 Corneal abrasion Diseases 0.000 claims description 9
- 229960004873 LEVOMENTHOL Drugs 0.000 claims description 9
- 229940041616 Menthol Drugs 0.000 claims description 9
- 206010010741 Conjunctivitis Diseases 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 8
- 230000002458 infectious Effects 0.000 claims description 7
- 229920001888 polyacrylic acid Polymers 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 150000003505 terpenes Chemical group 0.000 claims description 7
- 235000007586 terpenes Nutrition 0.000 claims description 7
- 208000010217 Blepharitis Diseases 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 208000008425 Protein Deficiency Diseases 0.000 claims description 6
- 210000001138 Tears Anatomy 0.000 claims description 6
- 239000000607 artificial tear Substances 0.000 claims description 6
- 239000000227 bioadhesive Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 201000010874 syndrome Diseases 0.000 claims description 6
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 4
- 229960003957 Dexamethasone Drugs 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229940059904 Light Mineral Oil Drugs 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000008347 soybean phospholipid Substances 0.000 claims description 4
- JJOFNSLZHKIJEV-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl JJOFNSLZHKIJEV-UHFFFAOYSA-N 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 3
- 229960004833 Dexamethasone phosphate Drugs 0.000 claims description 3
- 229960002344 Dexamethasone sodium phosphate Drugs 0.000 claims description 3
- 229960001193 Diclofenac Sodium Drugs 0.000 claims description 3
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims description 3
- 229960001629 FLUOROMETHOLONE ACETATE Drugs 0.000 claims description 3
- FAOZLTXFLGPHNG-KNAQIMQKSA-N Fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 3
- 229960003898 Flurbiprofen sodium Drugs 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229940014259 Gelatin Drugs 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 claims description 3
- 210000004175 Meibomian Glands Anatomy 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 3
- 229960001487 RIMEXOLONE Drugs 0.000 claims description 3
- QTTRZHGPGKRAFB-OOKHYKNYSA-N Rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims description 3
- 229940005550 Sodium alginate Drugs 0.000 claims description 3
- 229960004492 Suprofen Drugs 0.000 claims description 3
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 229940116362 Tragacanth Drugs 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 3
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 claims description 3
- 229960004875 difluprednate Drugs 0.000 claims description 3
- 229960001048 fluorometholone Drugs 0.000 claims description 3
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 229960000558 lodoxamide tromethamine Drugs 0.000 claims description 3
- 229960003744 loteprednol etabonate Drugs 0.000 claims description 3
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims description 3
- 229960001011 medrysone Drugs 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 235000019271 petrolatum Nutrition 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229960002800 prednisolone acetate Drugs 0.000 claims description 3
- 229960002943 prednisolone sodium phosphate Drugs 0.000 claims description 3
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N Bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 Carbomer Drugs 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229960003630 Ketotifen Fumarate Drugs 0.000 claims description 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N Nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
- 229960003655 bromfenac Drugs 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229960001002 nepafenac Drugs 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229960000371 rofecoxib Drugs 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229940054534 Ophthalmic Solution Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002997 ophthalmic solution Substances 0.000 abstract description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 8
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 abstract description 7
- 229960000846 Camphor Drugs 0.000 abstract description 7
- 241000723346 Cinnamomum camphora Species 0.000 abstract description 7
- 229930007890 camphor Natural products 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract description 6
- 230000000622 irritating Effects 0.000 abstract description 6
- 230000035807 sensation Effects 0.000 abstract description 6
- 239000011780 sodium chloride Substances 0.000 abstract description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract description 5
- 239000004327 boric acid Substances 0.000 abstract description 5
- 239000003974 emollient agent Substances 0.000 abstract description 5
- 230000002708 enhancing Effects 0.000 abstract description 5
- 239000012467 final product Substances 0.000 abstract description 5
- 239000008213 purified water Substances 0.000 abstract description 5
- 235000010339 sodium tetraborate Nutrition 0.000 abstract description 5
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 3
- 229940116229 Borneol Drugs 0.000 abstract description 3
- 229930006709 borneol Natural products 0.000 abstract description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 3
- 239000001110 calcium chloride Substances 0.000 abstract description 3
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract description 3
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 abstract 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 abstract 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010065062 Meibomian gland dysfunction Diseases 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 241000220479 Acacia Species 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 2
- 229940043234 Carbomer-940 Drugs 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- AUAGTGKMTMVIKN-UHFFFAOYSA-M sodium;2-(3-fluoro-4-phenylphenyl)propanoate Chemical compound [Na+].FC1=CC(C(C([O-])=O)C)=CC=C1C1=CC=CC=C1 AUAGTGKMTMVIKN-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 229940112822 Chewing Gum Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 210000000795 Conjunctiva Anatomy 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N Dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 229960001484 Edetic Acid Drugs 0.000 description 1
- 206010049796 Excoriation Diseases 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N Glycol stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 241001136616 Methone Species 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229940099429 Polyoxyl 40 Stearate Drugs 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 210000002265 Sensory Receptor Cells Anatomy 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N Tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 235000014569 mints Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960004599 sodium borate Drugs 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229940026752 topical Sulfonamides Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Abstract
ophthalmic preparation comprising: a. povidone-iodine at a concentration from about 0.1 % to about 2.5% said ophthalmic preparation, b. at least one member selected from the group consisting of a lubricant and a cooling agent, at a concentration which is not irritating to the eye; and c. optionally, one or more of the members selected from the group consisting of camphor, borneol, a lubricant, an emollient, a steroidal anti-inflammatory compound, and a non-steroidal anti-inflammatory compound. The compositions are useful to relieve mild ocular irritation, enhance ocular comfort, and to provide a refreshing effect and improved sensation, when the povidone-iodine solution is applied to the eye. An exemplary composition would be: 0.36%, 0.48%, or 0.6% PVP-I, by weight, as desired in the final product, and combining with 0.5% carboxymethylcellulose sodium, boric acid, calcium chloride, magnesium chloride, sodium borate, sodium chloride, and purified water. In an embodiment, a preserved ophthalmic solution comprises hydrochloric acid and/or sodium hydroxide to adjust pH. ally, one or more of the members selected from the group consisting of camphor, borneol, a lubricant, an emollient, a steroidal anti-inflammatory compound, and a non-steroidal anti-inflammatory compound. The compositions are useful to relieve mild ocular irritation, enhance ocular comfort, and to provide a refreshing effect and improved sensation, when the povidone-iodine solution is applied to the eye. An exemplary composition would be: 0.36%, 0.48%, or 0.6% PVP-I, by weight, as desired in the final product, and combining with 0.5% carboxymethylcellulose sodium, boric acid, calcium chloride, magnesium chloride, sodium borate, sodium chloride, and purified water. In an embodiment, a preserved ophthalmic solution comprises hydrochloric acid and/or sodium hydroxide to adjust pH.
Description
TITLE OF THE INVENTION
Non-Irritating Ophthalmic Povidone-Iodine Compositions
This application is a divisional of NZ 734815, which is itself a divisional of NZ 717107,
which is itself a divisional of NZ 700140, which is itself a divisional of NZ 600594, which is the
national phase entry in New Zealand of PCT international application
(published as ), filed 15 December 2010.
BACKGROUND
Ophthalmic compositions used for treatment of eye redness, ocular symptoms of allergies,
and microbial infection are often irritating to the eye upon instillation. For example, certain
iodine-containing ophthalmic compositions can be irritating to the eye upon instillation.
The use of a cooling agent, such as menthol, to provide a cooling effect on the skin and in
the oral cavity is known. Cooling agents have also been added to food products such as chewing
gum or mints, as well as to cigarettes, in order to provide a sensation of "coolness or freshness"
during consumption. Menthol has also been added to topical pharmaceutical compositions to
alleviate the sensation of inflammation and itch associated with bug bites and mild abrasions.
The sensation of coolness on the skin and mucosal surfaces resulting from the application
of menthol is believed to be due to a specific action on sensory nerve endings. It is believed that
cooling agents such as menthol exert their effect on cold receptors by interfering with the
mobility of calcium ions across the cell membrane. Certain preparations of menthol, for example,
have been perceived as being irritating to the eye, and consequently, menthol has not been
utilized extensively in ophthalmic preparations.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such documents,
or such sources of information, in any jurisdiction, are prior art, or form part of the common
general knowledge in the art.
The term “comprising” as used in this specification and claims means “consisting at least in
part of”. When interpreting statements in this specification and claims which include the term
“comprising”, other features besides the features prefaced by this term in each statement can also
be present. Related terms such as “comprise” and “comprises” are to be interpreted in similar
manner.
(followed by 1a)
BRIEF SUMMARY OF THE INVENTION
In a first aspect, the present invention provides an ophthalmic preparation comprising:
povidone-iodine (PVP-I) at a concentration of 0.36%, 0.48%, or 0.6% by weight, a cooling agent,
at a concentration of 0.01% to 10% by weight; and optionally, a steroidal anti-inflammatory
compound, or a non-steroidal anti-inflammatory compound, wherein said cooling agent is a
terpene, and the pH of the preparation is in the range of 3.5 to 6.5
In a second aspect, the present invention provides use of: povidone-iodine; a cooling agent;
and optionally, a steroidal anti-inflammatory compound, or a non-steroidal anti-inflammatory
compound; in the manufacture of an ophthalmic preparation for treating and/or prophylaxis of an
eye disorder or a microorganism infection of at least one tissue of the eye, wherein said povidone-
iodine is at a concentration of 0.36%, 0.48%, or 0.6% by weight, said cooling agent is a terpene
and is at a concentration of 0.01% to 10% by weight, and the pH of the preparation is in the range
of 3.5 to 6.5.
In a third aspect, the present invention provides use of: povidone-iodine; a cooling agent;
and optionally, a steroidal anti-inflammatory compound, or a non-steroidal anti-inflammatory
compound; in the manufacture of an ophthalmic preparation for treating and/or prophylaxis of a
microorganism infection of a tissue, wherein said povidone-iodine is at a concentration of 0.36%,
0.48%, or 0.6% by weight, said cooling agent is a terpene and is at a concentration of 0.01% to
% by weight, and the pH of the preparation is in the range of 3.5 to 6.5.
In a fourth aspect, the present invention provides the ophthalmic preparation of the first
aspect for treating and/or prophylaxis of an eye disorder or a microorganism infection of at
least one tissue of the eye.
In a fifth aspect, the present invention provides the ophthalmic preparation of the first
aspect for treating and/or prophylaxis of a microorganism infection of a tissue.
In the description in this specification reference may be made to subject matter which is not
within the scope of the appended claims. That subject matter should be readily identifiable by a
person skilled in the art and may assist in putting into practice the invention as defined in the
appended claims.
Disclosed herein is an ophthalmic preparation comprising povidone-iodine at a
concentration from about 0.1% to about 2.5%, a lubricant and/or a cooling agent. The lubricant
and/or cooling agent are present in the preparation at a concentration which is not irritating to the
eye. Optionally, an ophthalmic preparation also contains one or more of camphor, borneol, a
lubricant, an emollient, a steroidal anti-inflammatory compound, and a non-steroidal anti-
inflammatory compound.
(followed by 2)
In an aspect, PVP-I is present at a concentration of 0.2 to 2.0%, 0.3% to 1.5%, 0.36%
to 1.0%, and 0.4% to 0.75%. In another aspect, PVP-I is present at a concentration of about
0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about
0.7%, about 0.8%, about 0.9% and about 1.0%.
In an embodiment, the ophthalmic preparation includes a non-steroidal anti
inflammatory compound such as ketotifen fumarate, diclofenac sodium, nepafenac,
bromfenac, flurbiprofen sodium, suprofen, celccoxib, naproxen, rofccoxib, and any
combination thereof.
In another embodiment, the ophthalmic preparation includes a steroidal anti
inflammatory compound such as dexamethasone, dexamethasone alcohol, dexamethasone
sodium phosphate, fluorometholone acetate, fluorometholone alcohol, loteprednol etabonate,
medrysone, prednisolone acetate, prednisolone sodium phosphate, difluprednate, rimexolone,
hydrocortisone, hydrocortisone acetate, lodoxamide tromethamine, and any combination
thereof.
In an aspect, the ophthalmic preparation comprises at least one viscosity increasing
agent. A viscosity increasing agent may include polyvinyl alcohol, polyvinylpyrrolidone,
methyl cellulose, hydroxypropylmcthylccllulosc, hydroxycthylccllulosc,
carboxymethylccllulosc, hydroxypropylccllulose, and any combination thereof.
In an aspect, the ophthalmic preparation comprises at least one artificial tears-based
lubricant. An artificial tears-based lubricant may include propylene glycol, glycerin,
polyethylene glycol, dextran, blended polyvinyl alcohols, polyvinyl alcohol, polyethylene
glycol, light mineral oil, hydroxypropyl methylcellulose, hypromellose, carbopol, carbomer
940 (polyacrylic acid), polyvinyl pyrrolidone, white petrolatum, soy lecithin, and sodium
carboxyl methylcellulose.
In an aspect, the ophthalmic preparation comprises at least one bioadhesive agent. A
bioadhesive agent may include polyvinylpyrrolidone (PVP), xanthan gum, locust bean gum,
acacia gum, hydroxypropyl methylcellulose (HPMC), sodium alginate, pectin, gelatin,
carbomer, polyvinylalcohol, gellan gum, tragacanth, acacia, and sodium carboxymethyl
cellulose.
Disclosed herein is a method for treating and/or prophylaxis of an eye disorder or a
microorganism infection of at least one tissue of the eye comprising administration of one or
more doses of an ophthalmic preparation as disclosed herein to an eye.
In one aspect, a method includes prophylaxis of infection following corneal abrasion
or ocular surgery.
In an aspect, a method is used to treat a disorder such as conjunctivitis, corneal
abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal keratitis, herpesvirus-
related keratitis, ocular surface irregularity, tear deficiency, dry syndrome, meibomian gland
disfunction, blepharitis, uveitis, and a microorganism infection of at least one tissue of the
eye.
Disclosed herein is a method for treating and/or prophylaxis of a microorganism
infection of a non-ophthalmic tissue, comprising contacting the tissue with a composition as
disclosed herein.
DETAILED DESCRIPTION OF THE INVENTION
Disclosed herein are ophthalmic compositions comprising povidone-iodine
in the range of about 0.01% to about 10% (weight/weight or weight/volume) and a cooling
effective amount of a chemical agent to relieve mild ocular irritation, enhance ocular comfort,
and to provide a refreshing effect and improved sensation, when the povidone-iodine solution
is applied to the eye. Such an agent includes different chemical classes, including, but not
limited to, cooling agents such as menthol, menthol derivatives including methone glycerin
acetyl and menthyl esters, carboxamides, menthane glycerol kctals, alkyl substituted ureas,
sulfonamides, terpene analogs, furanones, and phosphine oxides; or camphor, and borneoi.
As will be understood by the skilled artisan, various cooling agents may have different
properties, and the amount and type of cooling agent to use may depend upon the components
of a desired composition, as well as the desired therapeutic or soothing effect, or the degree of
the effect, sought. Cooling agents may be used in a concentration range from about 0.001%
to about 10%, about 0.005% to about 10%, about 0.01% to about 10%, about 0.05% to about
%, about 0.1% to about 10%, about 0.25% to about 9%, about 0.5% to about 8%, about
0.75% to about 7%, about 0.9% to about 6%, or about 1.0% to about 5.0%. In an
embodiment, a cooling agent is present in a composition at a level of about 0.01%, about
0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%,
about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%,
about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about
1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2.0%. In an
embodiment, a cooling agent is present in a composition at a level of 0.01%, 0.02%, 0.03%,
0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%,
0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 3%, 4%,
or 5%.
The ophthalmic composition may further comprise an artificial tear-based lubricant to
improve the comfort. Artificial-tear based lubricants include, but are not limited to, propylene
glycol, glycerin, polyethylene glycol, dextran, blended polyvinyl alcohols, polyvinyl alcohol,
polyethylene glycol, light mineral oil, hydroxypropyl methylcellulosc, hypromellose,
carbopol, carbomer 940 (polyacrylic acid), polyvinyl pyrrolidone, white petrolatum, soy
lecithin, and sodium carboxyl methylcellulosc, as well as other agents known to those skilled
in the art, or any combination thereof. Typically, such lubricants arc employed at a level of
from 0.1% to 2% by weight. In an embodiment, the lubricants arc 1.0% propylene glycol,
0.3% glycerin, 2.7% blended polyvinyl alcohols, 1% polyvinyl alcohol, 1% polyethylene
glycol, light mineral oil, 0.3% hydroxypropyl methylcellulosc, 1.0% soy lecithin, 0.25% or
0.5% sodium carboxyl methylcellulose. In an embodiment, a lubricant is present in a
composition at a level of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about
0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%,
about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2.0%. In
an embodiment, a lubricant is present in a composition at a level of about 0.1%, 0.2%, 0.3%,
0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, about 1.0%, about 1.1%, about 1.2%, 1.3%, 1.4%,
1.5%, 1.6%, 1.7%, 1.8%, 1.9%, or 2.0%.
In an embodiment, a composition comprises povidone-iodine (PVP-1) at a
concentration in the range of about 0.1% to about 2.5%. In another embodiment, a
composition comprises povidone-iodine (PVP-I) at a concentration in the range between 0.2
and 1.5%, and in yet another embodiment, between 0.3% and 1.0%. In an embodiment, a
composition comprises PVP-I at a concentration in the range of about 0.2 to about 2.0%,
about 0.3% to about 1.5%, about 0.36% to about 1.0%, and about 0.4% to about 0.75%. In an
embodiment, a composition comprises PVP-I at a concentration of about 0.05%, about 0.1%,
about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about
0.9% or about 1.0%. In an embodiment, a composition comprises povidone-iodine PVP-I at a
concentration of 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9% or 1.0%. In
another embodiment, a composition comprises PVP-I at a concentration of about 2%, about
3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9% or about 10%.
Disclosed herein is a composition comprising
povidone-iodine at a concentration from about 0.1% to about 10%, a lubricant, and a cooling
agent at a concentration which is non-irritating to a non-ophthalmic tissue. Optionally, the
composition may further comprise one or more of camphor, bomeol, a lubricant, an emollient,
a steroidal anti-inflammatory compound, and a non-steroidal anti-inflammatory compound.
In yet another embodiment, an ophthalmic composition set forth herein is useful for a non-
ophthalmic application.
Methods
In an aspect, a composition of the invention is useful in the treatment of infections of
the conjunctiva and cornea. In another aspect, the broad spectrum antimicrobial activity of
povidone-iodine enables a composition of the invention to be used to treat ocular conjunctival
or corneal infection caused by mycobacteria, viruses, fungi, and amoeba. Additionally the
composition is useful in the infectious prophylaxis of patients recovering from ophthalmic
surgery. There are no currently available povidone-iodine solutions that are comfortable for
repeat application in the eye. The present invention provides, in part, compositions that meet
this need and/or that at least provide the public with a useful choice.
In an embodiment of the invention, an ophthalmic composition is provided that is
suitable for topical administration to an eye, effective for treatment and/or prophylaxis of a
microorganism infection or a disorder of at least one tissue of the eye. Prophylaxis may be,
for example, prophylaxis from infection following surgery, prophylaxis from infection after
birth for the newborn, or prophylaxis from accidental contact with contaminating material.
Accidental contact with contaminating material may occur, for example, during surgery or
during food processing.
Surprisingly, it was discovered that the compositions set forth herein, comprising
povidone-iodine combined with cooling agents set forth herein, and/or camphor, and/or
bomeol, and/or lubricants, and/or emollients, when present in a suitable pH range, eliminated
the undesired irritating effect of PVP-I to the eye.
In an embodiment, an ophthalmic composition may further comprise one or more of
(1) a penetration enhancer which enhances the penetration of povidone-iodine into the tissues
of the eye (this may be a topical anesthetic) (2) a co-solvent or a nonionic surface agent -
surfactant, which, for example, may be about 0.01% to 2% by weight; (3) a viscosity
increasing agent, which, for example, may be about 0.01% to 2% by weight; and (4) a suitable
ophthalmic vehicle.
The ophthalmic composition may be in the form of a solution, a suspension, an
emulsion, a preparation, an ointment, a cream, a gel, or a controlled-release/sustain-release
vehicle. By way of a non-limiting example, the composition may be in the form of a contact
lens solution, eyewash, eyedrop, and the like.
In an aspect, the ophthalmic composition may be used for treatment and/or
prophylaxis of a microorganism infection. The microorganism may be a bacterium, a virus, a
fungus, or an amoeba, a parasite, or a combination thereof. In an embodiment, the bacteria
may be a mycobacterium.
In an aspect, an ophthalmic composition may be used to treat a disorder such as, but
not limited to, conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial
keratitis, stromal keratitis, herpesvirus-related keratitis, ocular surface irregularity, tear
deficiency, dry syndrome, meibomian gland dysfunction, blepharitis and uveitis. In another
aspect, an ophthalmic composition may be used for prophylaxis of disorders such as
conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal
keratitis, herpesvirus-related keratitis, ocular surface irregularity, tear deficiency, diy
syndrome, meibomian gland dysfunction, blepharitis and uveitis.
Disclosed herein is a method for treating and/or
prophylaxis of an eye disorder or a microorganism infection of at least one tissue of the eye
comprising the step of administering one of more doses of an ophthalmic composition,
discussed above, to the eye. The eye disorder may be, for example, a microorganism infection
of at least one tissue of the eye, conjunctivitis, corneal abrasion, ulcerative infectious keratitis,
epithelial keratitis, stromal keratitis, herpes virus-related keratitis, ocular surface irregularity,
tear deficiency, dty syndrome, meibomian gland dysfunction, and blepharitis. The
microorganism may be bacteria (e.g., mycobacteria), virus, fungi, or amoebae.
In an embodiment, the dose volume administered to a subject may be between about
microliters and about 200 microliters, in another embodiment, between about 20
microliters and 100 microlilcrs, and in another embodiment, between about 50 microliters and
about 80 microliters, or about one drop per eye. Two or more drops may be added to an eye.
Treatment or soothing of an eye may be effected by adding a single drop of composition
disclosed herein, or by adding two or more drops, as required to achieve the desired result.
In an embodiment, administration frequency may be between 1 and 24 times a day. In
an embodiment, administration frequency may be between 1 and 48 times a day. In another
embodiment, administration frequency may be between 2 and 24 times a day. In another
embodiment, administration frequency may be between 2 and 4 times a day. In another
embodiment, administration frequency may be twice a day. In another embodiment,
administration frequency may be once a day. In another embodiment, administration
frequency may be less frequent than once a day. In another embodiment, administration
frequency may be on demand, as therapeutic or soothing treatment is required or desired.
In an embodiment, a composition disclosed herein is used for prophylaxis and/or
treatment of a non-ophthalmic tissue by contacting the tissue with the composition.
Additional Conmositions
Compositions and preparations disclosed herein may further comprise one or more
non-steroidal anti-inflammatory compounds. Non-steroidal anti-inflammatory compounds
include, but are not limited to, ketotifen fumaratc, diclofenac sodium, ncpafcnac, bromfcnac.
flurbiprofen sodium, suprofen, cclecoxib, naproxen, rofecoxib, and any combination thereof.
Compositions and preparations disclosed herein may further comprise one or more steroidal
anti-inflammatory compounds. Steroidal anti-inflammatory compounds include, but are not
limited to dexamethasone, dexamethasonc alcohol, dexamethasone sodium phosphate,
fluorometholone acetate, fluorometholone alcohol, loteprednol etabonate, medrysone,
prednisolone acetate, prednisolone sodium phosphate, difluprednate, rimexolone,
hydrocortisone, hydrocortisone acetate, lodoxamide tromethamine, and any combination
thereof. Steroidal and non-steroidal compounds may be combined in a single composition or
preparation contemplated or disclosed herein. In an embodiment, a steroidal anti
inflammatory compound or a non-steroidal anti-inflammatory compound is present in the
composition or preparation at a level of about 0.01% to about 10%. In an embodiment, a
steroidal anti-inflammatory compound or a non-steroidal anti-inflammatory compound is
present in the composition or preparation at a level of about 0.01%, about 0.02%, about
0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%,
about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about
0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%,
about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2.0%.
The compositions and preparations disclosed herein can be administered as solutions,
suspensions, emulsions (dispersions), gels, creams, or ointments in a suitable ophthalmic
vehicle. In any of the compositions of this disclosure for topical administration, such as
topical administration to the eye, the mixtures arc preferably formulated as aqueous solutions
at a pH of 3.5 to 6.5. Preferentially the pH was adjusted to between 4 and 5. This pH range
may be achieved by the addition of acids/bases to the solution.
In an embodiment, an ophthalmic composition may comprise an optional co-solvent.
In another embodiment, the solubility of the components of the present compositions may be
enhanced by a surfactant or other appropriate co-solvent in the composition. Such co-solvents
or surfactants include polysorbate -20, -60, and -80, a polyoxyethylcnc/polyoxypropylcnc
surfactant (e.g. Pluronic F-68, F-84 and P-103), cyclodextrin, tyloxapol, PEG 35 Castor oil
(Cremophor EL), polyoxyl 40 Stearate (Myrj 52), other agents known to those skilled in the
art, or a combination thereof. Typically, such co-solvents arc present at a level of from about
0.01% to about 2% by weight.
In an embodiment, a composition may comprise an optional agent that can increase
viscosity. As will be understood by the skilled artisan when armed with the present disclosure.
it may be desirable to increase viscosity above that of a simple aqueous solution in order to
increase ocular absorption of the active compound, to decrease variability in dispensing the
formulation, to decrease physical separation of components of a suspension or emulsion of the
formulation and/or to otherwise improve the ophthalmic formulation. Such viscosity
enhancing agents include, but are not limited to, polyvinyl alcohol, polyvinyl pyrrolidone,
methyl cellulose, hydroxypropylmethyl cellulose, hydroxycthyl cellulose, carboxymethyl
cellulose, hydroxypropyl cellulose, other agents known to those skilled in the ait, or any
combination thereof. Such agents arc typically employed at a level of from about 0.01% to
about 2% by weight.
In another aspect, bioadhesive agents may comprise the compositions, in order to
increase the retention time of the drug gradient over a biological substrate. The bioadhesive
agents include, but are not limited to, polyvinylpyrrolidone (PVP), xanthan gum, locust bean
gum, acacia gum, hydroxypropyl methylccllulo.se (HPMC), sodium alginate, pectin, gelatin,
carbomcr, polyvinylalcohol, gcllan gum, tragacanth, acacia, and sodium carboxymethyl
cellulose, as well as other agents known to those skilled in the art, or any combination thereof.
In yet another embodiment, compositions of the invention may comprise viscoelastic agents
such as methyl cellulose, carboxymethyl cellulose, hydroxycthyl cellulose, polyvinyl alcohol,
dextran, chondroitin sulfate and salts thereof, and hyaluronic acid and salts thereof.
In another aspect, compositions of the invention may comprise one or more buffering
agents, isotonizing agents, solubilizers, stabilizers, chelating agents, and any combinations
thereof. Such additional components may be used at concentrations that provide enhanced
comfort or therapeutic properties to the PVP-I compositions disclosed herein. In another
aspect, such additional components may be used at concentrations in which the additional
component itself has a therapeutic and/or soothing effect, in addition to the effect obtained
from the PVP-I compositions disclosed herein.
EXAMPLES
The invention is now described with reference to the following Examples. These
Examples are provided for the purpose of illustration only and the invention should in no way
be construed as being limited to these Examples, but rather should be construed to encompass
any and all variations which become evident as a result of the teaching provided herein.
Example 1: Preparation of non-irritating PVP-1 ophthalmic solution 1
By way of a non-limiting example, a PVP-I ophthalmic solution is prepared using
0.36%, 0.48%, or 0.6% PVP-I, by weight, as desired in the final product, and combining with
1.8% povidone, ethanol (0.1%), boric acid, camphor, poloxamcr 407, polysorbatc 80,
potassium chloride, sodium borate, sodium chloride, and purified water.
Example 2: Prenaration of non-irritatim> PVP-I ophthalmic solution 2
By way of a non-limiting example, a PVP-I ophthalmic solution is prepared using
0.36%, 0.48%, or 0.6% PVP-I, by weight, as desired in the final product, and combining with
0.2% polysorbatc 80, ethanol (0.1%), boric acid, edetate disodium, menthol, sodium borate,
and purified water.
Example 3: Preparation of PVP-I preserved ophthalmic solution 3
By way of a non-limiting example, a PVP-I ophthalmic solution is prepared using
0.36%, 0.48%, or 0.6% PVP-I, by weight, as desired in the final product, and combining with
0.5% carboxymcthylccilulosc sodium, boric acid, calcium chloride, magnesium chloride,
sodium borate, sodium chloride, and purified water. In an embodiment, a preserved
ophthalmic solution comprises hydrochloric acid and/or sodium hydroxide to adjust pH.
The invention has been described herein by reference to certain embodiments.
However, as variations thereof will become apparent to those skilled in the ail, when armed
with the disclosure set forth herein, the invention is not to be considered as limited thereto.
All patents, patent applications, and references cited herein arc hereby incorporated by
reference in their entirety.
Claims (27)
1. An ophthalmic preparation comprising: povidone-iodine (PVP-I) at a concentration of 0.36%, 0.48%, or 0.6% by weight, a cooling agent, at a concentration of 0.01% to 10% by weight; and optionally, a steroidal anti-inflammatory compound, or a non-steroidal anti- inflammatory compound, wherein said cooling agent is a terpene, and the pH of the preparation is in the range of 3.5 to 6.5.
2. The ophthalmic preparation of claim 1, wherein the PVP-I is present at a concentration of 0.36% by weight.
3. The ophthalmic preparation of claim 1, wherein the PVP-I is present at a concentration of 0.48% by weight.
4. The ophthalmic preparation of claim 1, wherein the PVP-I is present at a concentration of 0.6% by weight.
5. The ophthalmic preparation of any one of claims 1-4, wherein said non-steroidal anti- inflammatory compound is selected from the group consisting of ketotifen fumarate, diclofenac sodium, nepafenac, bromfenac, flurbiprofen sodium, suprofen, celecoxib, naproxen, rofecoxib, and any combination thereof.
6. The ophthalmic preparation of any one of claims 1-5, wherein said steroidal anti- inflammatory compound is selected from the group consisting of dexamethasone, dexamethasone alcohol, dexamethasone sodium phosphate, fluorometholone acetate, fluorometholone alcohol, loteprednol etabonate, medrysone, prednisolone acetate, prednisolone sodium phosphate, difluprednate, rimexolone, hydrocortisone, hydrocortisone acetate, lodoxamide tromethamine, and any combination thereof.
7. The ophthalmic preparation of any one of claims 1-6, wherein the steroidal anti- inflammatory compound is dexamethasone.
8. The ophthalmic preparation of any one of claims 1-7 wherein said preparation further comprises a viscosity increasing agent.
9. The ophthalmic preparation of claim 8 wherein said viscosity increasing agent is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and any combination thereof.
10. The ophthalmic preparation of any one of claims 1-9, wherein the preparation comprises at least one artificial tears-based lubricant.
11. The ophthalmic preparation of claim 10, wherein said artificial tears-based lubricant is selected from the group consisting of propylene glycol, glycerin, polyethylene glycol, dextran, blended polyvinyl alcohols, polyvinyl alcohol, light mineral oil, hydroxypropyl methylcellulose, hypromellose, polyacrylic acid, polyvinyl pyrrolidone, white petrolatum, soy lecithin, sodium carboxyl methylcellulose, and any combination thereof.
12. The ophthalmic preparation of any one of claims 1-11, further comprising at least one bioadhesive agent.
13. The ophthalmic preparation of claim 12, wherein said bioadhesive agent is selected from the group consisting of polyvinylpyrrolidone (PVP), xanthan gum, locust bean gum, acacia gum, hydroxypropyl methylcellulose (HPMC), sodium alginate, pectin, gelatin, carbomer, polyvinylalcohol, gellan gum, tragacanth, acacia, sodium carboxymethyl cellulose, and any combination thereof.
14. The ophthalmic preparation of any one of claims 1 to 13, wherein the cooling agent is menthol.
15. Use of: povidone-iodine; a cooling agent; and optionally, a steroidal anti-inflammatory compound, or a non-steroidal anti- inflammatory compound; in the manufacture of an ophthalmic preparation for treating and/or prophylaxis of an eye disorder or a microorganism infection of at least one tissue of the eye, wherein said povidone-iodine is at a concentration of 0.36%, 0.48%, or 0.6% by weight, said cooling agent is a terpene and is at a concentration of 0.01% to 10% by weight, and the pH of the preparation is in the range of 3.5 to 6.5.
16. The use of claim 15, wherein the ophthalmic preparation is as defined in any one of claims 2-14.
17. The use of claim 15 or 16 wherein said ophthalmic preparation is for prophylaxis of infection following corneal abrasion or ocular surgery.
18. The use of claim 15 or 16 wherein said eye disorder is selected from the group consisting of conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal keratitis, herpesvirus-related keratitis, ocular surface irregularity, tear deficiency, dry syndrome, meibomian gland disfunction, blepharitis, uveitis, and a microorganism infection of at least one tissue of the eye.
19. The use of any one of claims 15, 16 and 18, wherein the eye disorder is conjunctivitis.
20. Use of: povidone-iodine; a cooling agent; and optionally, a steroidal anti-inflammatory compound, or a non-steroidal anti- inflammatory compound; in the manufacture of an ophthalmic preparation for treating and/or prophylaxis of a microorganism infection of a tissue, wherein said povidone-iodine is at a concentration of 0.36%, 0.48%, or 0.6% by weight, said cooling agent is a terpene and is at a concentration of 0.01% to 10% by weight, and the pH of the preparation is in the range of 3.5 to 6.5.
21. The ophthalmic preparation of any one of claims 1-14 for treating and/or prophylaxis of an eye disorder or a microorganism infection of at least one tissue of the eye.
22. The ophthalmic preparation of claim 21 for prophylaxis of infection following corneal abrasion or ocular surgery.
23. The ophthalmic preparation of claim 21 wherein said eye disorder is selected from the group consisting of conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal keratitis, herpesvirus-related keratitis, ocular surface irregularity, tear deficiency, dry syndrome, meibomian gland disfunction, blepharitis, uveitis, and a microorganism infection of at least one tissue of the eye.
24. The ophthalmic preparation of claim 21 or 23 wherein the eye disorder is conjunctivitis.
25. The ophthalmic preparation of any one of claims 1-14 for treating and/or prophylaxis of a microorganism infection of a tissue.
26. An ophthalmic preparation of any one of claims 1-11 and 21-25 substantially as herein described with reference to any example thereof.
27. Use of any one of claims 15-20 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28669709P | 2009-12-15 | 2009-12-15 | |
US61/286,697 | 2009-12-15 | ||
NZ734815A NZ734815A (en) | 2009-12-15 | 2010-12-15 | Non-irritating ophthalmic povidone-iodine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ751915A NZ751915A (en) | 2020-09-25 |
NZ751915B2 true NZ751915B2 (en) | 2021-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2784492C (en) | Non-irritating ophthalmic povidone-iodine compositions | |
EP2291081B1 (en) | Povidone iodine, a novel alternative preservative for ophthalmic compositions | |
JPWO2007108541A1 (en) | Ophthalmic composition containing xanthan gum and glucose | |
JPWO2006049250A1 (en) | Intraocular transfer-promoting aqueous eye drops | |
KR101934767B1 (en) | Novel ophthalmic composition and methods of use | |
US11241426B2 (en) | Aqueous composition for ophthalmic or nasal administration | |
JP4752987B2 (en) | External preparation composition | |
AU2017235979B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
JP2005008596A (en) | Ophthalmological composition | |
NZ751915B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
AU2019268200B2 (en) | Povidone iodine, a novel alternative preservative for ophthalmic compositions | |
JP5299449B2 (en) | External preparation composition | |
JP5627235B2 (en) | Ophthalmic composition | |
JP4470393B2 (en) | Eye drops that are stable | |
JP2011011984A (en) | Therapeutic agent for pseudomyopia |